|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||9.27 - 9.45|
|52 Week Range||3.21 - 9.70|
|PE Ratio (TTM)||-8.68|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Spectrum Pharmaceuticals, Inc. (SPPI) initiated the registrational phase III study of qapzola in patients with non-muscle invasive bladder cancer (NMIBC) as per the FDA's requirement.
Categories: Yahoo FinanceGet free summary analysis Spectrum Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Spectrum Pharmaceuticals, Inc. – Teva Pharmaceutical Industries Limited Sponsored ADR, Celgene Corporation, Curis, Inc., Seattle Genetics, Inc., Novartis AG Sponsored ADR, Pfizer Inc., Abbott Laboratories, Bristol-Myers Squibb Company, ... Read more (Read more...)
Ligand's (LGND) earnings and revenues beat estimates. Total revenue also rises year over on the back of higher royalty benefits. The company ups its outlook for 2017.